Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal

 
• By Alaric DeArment

Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.

Wireframe DNA sequence molecules structure mesh. Hands of robot and human touching on DNA connecting in virtual interface on future. Artificial intelligence technology concept. Vector illustration.
Pfizer and CytoReason built on their AI/ML pact with a new deal • Source: Shutterstock

More from AI

More from Digital Technologies